Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2000-02-09
2001-11-20
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S484000, C424S486000
Reexamination Certificate
active
06319521
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the use of lactide-co-glycolide copolymers to form microparticles using precipitation by compressed antisolvents.
BACKGROUND OF THE INVENTION
The technique of precipitation by compressed antisolvents (PCA) has been used to manufacture linear-homopolymer microparticles to encapsulate a variety of materials for the controlled release of the encapsulated materials. Encapsulation of materials, particularly pharmaceutical drugs, into biodegradable polymers using PCA is attractive because of high encapsulation efficiency (Falk et al,
J. Controlled Release
, 44:77-85 (1997)), low residual solvent levels, low processing temperatures (Falk & Randolph,
Pharmaceutical Research
, 15(8):1233-1237 (1998)), and the production of micron sized particles (Randolph et al,
Biotech. Progress
, 9:429-435 (1993); Dixon et al.,
AIChE J
., 39(1):127-139 (1993)).
However, the use of PCA at times produces certain undesirable results. For example, linear-homopolymers, such as poly(lactide), encapsulated microparticles release the encapsulated materials over several months, which is a relatively long period of time. Such long release times are particularly undesirable for many pharmaceutical delivery applications, because of potential adverse patient reactions. In addition, the high solubility of supercritical carbon dioxide (CO
2
), which enables the rapid extraction of solvent from the polymer during PCA, also causes large quantities of CO
2
to diffuse into the polymer. Acting as a diluent, CO
2
lowers the glass transition temperature (T
g
) of the polymer. Polymers susceptible to a suppression of T
g
below the operating temperature of the PCA system may form agglomerated particles or thin films during precipitation.
The study of CO
2
effects on polymers is not new. T
g
suppression was originally observed in the creep rates recorded for poly(carbonate) pipes pressurized with CO
2
(Hojo & Findley,
Polymer Engr. Science
, 13:255-265 (1973)). Eventually this behavior led to new production methods for polymer foams, the extraction of low molecular weight compounds from polymers, and the impregnation of polymers with chemical additives (Wissinger & Paulaitis,
Industrial & Engr. Chem. Res
., 30:842-851 (1991)). Experimental measurements of T
g
suppression by CO
2
include observing the relaxation of mechanical properties (Wang et al.,
J. Polymer Sci. Part B: Polymer Physics
, 20(6):1371-84 (1982)), differential scanning calorimetry (Chiou et al.,
J. Applied Polymer Sci
., 30:2633-2642 (1985)), and creep compliance (Condo & Johnston,
J. Polymer Sci: Part B: Polymer Physics
, 32:523-533 (1994)). Thermodynamic models using lattice fluid theory and the Gibbs-Di Marzio criterion predict glass transition temperatures as a function of pressure remarkably well (Condo et al.,
Macromolecules
, 25(23)6119-6127 (1992); Kalosiros & Paulaitis,
Chem. Engr. Sci
., 49(5):659-668 (1994)). Together, models and experiments led to the classification of four fundamental polymer behaviors, and the understanding that the T
g
of a polymer or copolymer at a particular pressure depends on the pure polymer T
g
and the solubility of CO
2
within the polymer. Thus research to date on viable polymers for PCA has been limited to measuring or predicting a polymer's glass transition temperature after interaction with compressed carbon dioxide. As a result, previous theory deemed all polymers with glass transition temperatures below the operating conditions of the PCA system as unusable.
Bodmeier et al.,
Pharmaceutical Research
, 12(8):1211-1217 (1995) reported some interesting observations while determining suitable polymers for PCA. Bodmeier et al. based the compatibility of a polymer on the degree of swelling observed in compressed CO
2
. From the six polymers investigated, they reported the highly crystalline and the semi-crystalline polymers were generally unaffected by high pressure CO
2
exposure, while all the amorphous polymers agglomerated under similar conditions.
Poly(lactide-co-glycolide) is a common biodegradable pharmaceutical polymer. The copolymer has been extensively used for suture material and, in the last decade, has been explored as a potential drug release medium. However, the PCA technique was believed to be unsuitable for the copolymer because compressed carbon dixoide severely affects the mechanical properties of the copolymer and prevents formation of microparticles.
Accordingly, a need exists for methods of using lactide-co-glycolide copolymers in PCA to form microparticles. The present invention satisfies this need and provides related advantages.
SUMMARY OF THE INVENTION
The invention generally relates to novel methods for making poly(lactide-co-glycolide) microparticles and using the microparticles as delivery vehicles for the controlled release of a variety of compounds, including pharmacueticals. The invention is based on the discovery of a family of copolymers that can be successfully manufactured into microparticles above their glass transition as long as sufficient crystalline structure exists to maintain suitable mechanical strength.
Accordingly, the methods for making the microparticles in a precipitation by compressed antisolvent (PCA) process are generally accomplished by first obtaining any “semi-crystalline copolymer” having a semi-crystalline structure, such as poly(lactide-co-glycolide), that above its glass transition temperature will retain sufficient degree of its crystalline strength to form microparticles. Thereafter, the copolymer is exposed to a compressed antisolvent to form the semi-crystalline copolymeric microparticles. The antisolvent used in the methods is preferably carbon dioxide, and more preferably carbon dioxide in a supercritical or liquid state.
The critical crystallinity of suitable copolymers (below which insufficient crystalline structure exists to form microparticles during PCA) depends on a variety of factors including, for example, the molecular weight of the copolymer, the operating temperature of the PCA process, the glass transition temperature of the copolymer and the mechanical strength of the copolymer. Preferably, the critical crystallinity of the copolymer is in the range of about 10% to about 15%, and more preferably about 12% particularly when the molecular weight of the copolymer is about 100 kDa.
The invention also relates to the microparticles composed of any copolymers designed so that the critical crystallinity is achieved to facilitate production by the above methods, including the microparticles produced by the above methods. Examples of suitable semi-crystalline copolymers to form microparticles include polystyrene and polyethers, as well as the lacide-co-glycolide copolymers.
The invention further provides systems for the controlled release of various compounds that are encapsulated in the semi-crystalline copolymeric microparticles and to methods of using the systems to control the release of the compounds to a target environment over a predetermined period of time. The controlled release of the compounds is accomplished by varying the ratio of the copolymer components. Depending on the intended use, the ratio can range from 100:0 to 0:100 of the individual components. For example, a ratio of 50:50 to 30:70 of poly(lactide) to poly(glycolide) is particularly useful for the controlled release of pharmaceutical agents when a shorter release time is desired. Thus, the release time using the present family of copolymers can range from weeks to months by varying this ratio.
REFERENCES:
patent: 5232707 (1993-08-01), Lokensgard
patent: 6126919 (2000-10-01), Stefely et al.
Falk, III Richard Frank
Lengsfeld Corinne
Randolph Theodore W.
Di Nola-Baron Liliana
Medlen & Carroll LLP
Page Thurman K.
University Technology Corporation
LandOfFree
Microparticles of lactide-co-glycolide copolymers and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Microparticles of lactide-co-glycolide copolymers and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microparticles of lactide-co-glycolide copolymers and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2597838